Passardi SA, Galimberti GN, Galimberti RL

Language: Spanish
References: 19
Page: 12-16
PDF size: 243.37 Kb.

ABSTRACT

Daylight mediated photodynamic therapy (TFDLD) is a new treatment virtually painless for the treatment of actinic keratosis (AK) and photodamage in which no incubation time is needed and used as a source of light the sun.
Objetives: to evaluate the effectiveness of treatment for 12 weeks actinic keratosis, the most frequent adverse reactions and patient satisfaction to treatment.
Methodology: from March till June 2015, in the city of Buenos Aires, recruited 66 patients with actinic keratosis grade I, II and III located on the face and scalp. We use 16% methyl aminolevulinate cream that was applied in the treatment area after skin preparation, it was activated by sunlight exposure after two hours outdoors. Actinic keratoses were recorded by type and location prior to treatment and at three months.
Results: in 66 patients a total of 1 573 AK grade I, II and III were treated. Clinically they sent 68% of all treated AK, the response was 82% higher in the AK grade I, grade II then 61% and 24% for grade III. Erythema, scales and crusts were mild and seven days were not present. Patients reported little or no pain during the procedure.
Discussion: TFDLD is a simple and painless for AK varying degrees of treatment, although they have the best answer for grade I and II. It is dependent on the weather and the patient’s adherence to the indications received by the dermatologist.

REFERENCES

1. Braathen, L., Szeimies, R., Basset-Seguin, N., Bissonnette, R. et al., “Guidelines on the use of photodynamic theraphy for nonmelanoma skin cancer: an international consensus”, J Am Acad Dermatol, 2007, 56: 125-143.

2. Morton, C., Szeimies, R., Sidoroff, A. y Braathen, L., “European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications actinics keratoses, Bowen’s disease, basal cell carcinoma”, J Eur Acad Dermatol Venerol, 2013, 27: 536-544.

3. Calzavara-Pinton, Venturini M., “Fototerapia y fotoquimioterapia”, en Giannetti, A. y Galimberti, R., Tratado de dermatología, Roma, Ed. Piccin, 2012, 2583-2587.

4. Morton, C., McKenna, K. y Rhodes, L., “Guidelines for topical photodynamic therapy: update”, Br J Dermatol, 2008, 159: 1245-1266.

5. Gilaberte, Y. et al., “Terapia fotodinámica en dermatología”, Actas Dermosifiliogr, 2006, 97: 83-102.

6. Truchuelo, M. et al., “Effectiveness of photodynamic therapy in Bowen’s disease: an observational and descriptive study in 51 lesions”, J Eur Acad Dermatol Venereol, 2012, 26: 868–874.

7. Marecos, R., Galimberti, G., Passardi, S., Galimberti, R. y Guzmán Fawcett, A., “Tratamiento de las queratosis actínicas con terapia fotodinámica con luz de día en Argentina”, DCMQ, 2014, 12 (4): 231–236.

8. Wiegell, S.R., Haedersdal, M., Eriksen, P. y Wulf, H.C., “Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home based daylight exposure: a doublé blinded randomized clinical trial”, Br J Dermatol, 2009, 160: 1308-1314.

9. Wiegell, S.R. et al., “Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology”, J Eur Acad Dermatol Venereol, 2012, 26: 673-679.

10. Pérez-Pérez, L., García Gavin, J. et al., “Terapia fotodinámica con luz de día en España: ventajas y limitaciones”, Actas Dermosifiliogr, 2014, 105: 663-674.

11. Wiegell, S.R., Fabricius, S., Gniadecka, M. y Stender, I.M., “Daylight mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study”, Br J Dermatol, 2012, 166: 1327-1332.

12. Grinblat, B.M. et al., “Daylight photodynamic therapy for actinic keratosis in São Paulo, Brazil”, Photodermatol Photoimmunol Photomed, 2015, 31(1): 54-56.

13. Olsen, E.A. et al., “A double blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck”, J Am Acad Dermatol, 1991, 24: 738-743.

14. Rubel, D.M. et al., “Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial”, Br J Dermatol, 2014, 171 (5): 1164-1171.

15. Braathen, L.R., “Daylight photodynamic therapy in private practice in Switzerland: gain without pain”, Acta Derm Venereol, 2012, 92: 585-663.

16. Lacour, J.P. et al., “Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomized, investigator-blinded, controlled, phase 3 study throughout Europe”, en prensa, JEADV, 2015.

17. Togsverd-Bo, K., “Combination of ablative fractional laser and daylight mediated photodynamic therapy for actinic keratosis in organ transplant recipients a randomized controlled trial”, Br J Dermatol, 2015, 172 (2): 467-474.

18. Lim, H.K., Jeong, K.H., Kim, N.I. y Shin, M.K., “Non ablative fractional laser as tool to facilitate skin penetration of 5-aminolaevulinic acid with minimal skin disruption: a preliminary study”, Br J Dermatol, 2014, 170: 1336-1340.

19. Wiegell, S.R. et al., “Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin ix-weighted daylight doses measured in six geographical locations”, Br J Dermatol, 2013, 168: 186-191.